Danaher Stock: Buy After a 36% Decline?
💡 Puntos Clave
Danaher's stock, down 36% from its peak, presents a compelling buying opportunity as its business recovers and its valuation sits well below historical norms.
What Happened to Danaher?
Danaher (DHR), a legendary life sciences conglomerate, has delivered an astounding 52,700% return for investors since its founding in 1969. However, the stock has faced significant headwinds over the past five years, currently trading 36% below its all-time high.
The company's struggles stem from a post-pandemic hangover. Its business, which includes diagnostics and biotech tools, boomed during COVID-19 due to testing and vaccine manufacturing demand. Once that surge normalized, revenue declined sharply.
Adding to the pressure, sales in China, a key market representing about 11% of revenue, have been soft for several years. This combination of factors led to years of declining sales, which soured investor sentiment on the stock.
Signs of a turnaround emerged in 2024, with revenue bottoming and beginning to grow again. The company then announced a major $9.9 billion cash acquisition of Masimo (MASI), a leader in pulse oximetry technology, in February.
Why This Matters for Investors
This matters because Danaher appears to be pivoting from a multi-year slump back to its growth trajectory. The acquisition of Masimo is a strategic move that complements Danaher's existing diagnostics business and adds over $1.5 billion in annual sales.
Financially, the deal is expected to add $530 million in EBITDA by 2027. Since it's a cash acquisition, it won't dilute existing shareholders. This incoming profit stream should boost Danaher's per-share financials.
The company's valuation has become much more attractive. Historically, Danaher traded at an average price-to-earnings (P/E) ratio of about 32. Today, it trades at just over 22 times this year's estimated earnings, representing a significant discount.
Danaher started its 2025 fiscal year strong, with Q1 non-GAAP earnings growing 9.5% year-over-year and beating expectations. Management forecasts over $5 billion in free cash flow this year, providing ample fuel for further growth or acquisitions.
Analysts project average annual earnings growth of 8-9% over the next several years. With a proven business system and a cheaper valuation, the stock's risk-reward profile has improved for long-term investors.
Fuente: The Motley Fool
Análisis generado por el modelo cuantitativo de Bobby AI, revisado y editado por nuestro equipo de investigación. Esto no constituye asesoramiento financiero. Investigue por su cuenta antes de tomar decisiones de inversión.
Bobby Insight
Danaher stock is a buy for patient investors seeking a high-quality company at a discounted price.
The core business is recovering, a major accretive acquisition is underway, and the stock trades at a compelling valuation compared to its own history. While challenges in China persist, the company's proven Danaher Business System and strong cash generation provide a solid foundation for future growth.
¿Cómo Me Afecta?
